Abstract CT312: Ponatinib is well tolerated and active in patients with relapsed/refractory philadelphia positive leukemias: The Bologna experience
Cristina Papayannidis(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Giovanni Martinelli(University of Bologna), Maria Teresa Bochicchio(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Valentina Robustelli(University of Bologna), Simona Soverini(University of Bologna), Anna Ferrari(University of Bologna), Andrea Ghelli Luserna di Rorà(Fondazione Pisa), Chiara Sartor(University of Bologna), Maria Chiara Abbenante(University of Bologna), Emanuela Ottaviani(University of Bologna), Giuseppe Cimino(Policlinico Umberto I), Fabio Ciceri(Vita-Salute San Raffaele University), Silvia Piccari(University of Bologna), Simona Luatti(University of Bologna), Caterina De Benedittis(University of Bologna), Sarah Parisi(University of Bologna), Renato Fanin(University of Udine), Ilaria Iacobucci(St. Jude Children's Research Hospital), Nicoletta Testoni(Thrombolysis in Myocardial Infarction Study Group), Elisa Lani(University of Bologna), Viviana Guadagnuolo(University of Bologna), Carmen Baldazzi(University of Bologna), Federica Frabetti(University of Bologna), Alberto Conficoni(University of Bologna), Paolo Di Bartolomeo(Martin University), Roberto Di Lorenzo(Gruppo Italiano per il Trapianto di Midollo Osseo), Claudia Venturi(University of Bologna), Stefania Paolini(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola)
Cited by 0
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k